Cytotoxic T Lymphocytes
Cytotoxic T Lymphocytes - Related Videos
03:00
An Assay to Evaluate Immunodominance in Cytotoxic T Lymphocyte Responses
0 Views •
2025
The video showcases a flow cytometry-based assay for assaying immunodominance in cytotoxic T lymphocytes or CTL responses. Injected fluorescent target cells exhibit varying fluorescence corresponding to immunogenic epitopes. Post-spleen collection and sorting reveal a reduction in high-intensity fluorescent cells, confirming immunodominance in CTL responses.
04:45
An Immunological Technique to Monitor Adjuvant-Mediated Cytotoxic T Lymphocyte Generation
0 Views •
2025
The video demonstrates an immunological method to monitor in vivo adjuvant-induced cytotoxic T lymphocyte or CTL production. A mouse is pre-injected with genetically engineered, proliferative dye-stained donor CD8+ T lymphocytes. Subcutaneous injection of ovalbumin with adjuvants generates cytotoxic CD8+ T lymphocytes that are identified post-harvesting through immunostaining and flow cytometry.
10:01
Radial Mobility and Cytotoxic Function of Retroviral Replicating Vector Transduced, Non-adherent Alloresponsive T Lymphocytes
0 Views •
2015
We describe a protocol to monitor radial mobility of non-adherent immune cells in vitro using a cell sedimentation manifold/slide apparatus. Cell migration is tracked on monolayers of tumor cells or on extracellular matrix proteins. Examination by light and fluorescence microscopy allows for observation of cell mobility and cytotoxic functionality.
12:12
Methods to Assess Beta Cell Death Mediated by Cytotoxic T Lymphocytes
0 Views •
Cited by 14 •
2011
Cell-mediated lymphocytotoxicity (CML) assays can be used to test autoreactive responses and study mechanisms of cell death in vitro. However, using live-cell confocal microscopic imaging techniques with fluorescent dyes, the type and kinetics of cell death as well as the pathways utilized can be studied in greater detail.
11:18
Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
0 Views •
Cited by 27 •
2012
Here we describe the first good manufacturing practice (GMP)-compliant method of producing virus-specific cytotoxic T lymphocytes (CTL) from umbilical cord blood, a source of predominantly naîve T cells.
FAQs
Specificity begins when a CTL's T-cell receptor recognizes a particular antigen displayed on major histocompatibility complex class I molecules. This recognition distinguishes target cells according to the antigen they present, rather than relying on a general response to cellular abnormality. In infection and cancer studies, this antigen-presentation step explains how adaptive immune defense is directed toward selected cells.
The close contact formed with a recognized target cell concentrates the CTL response at the intended site. CTLs then release perforin and granzymes; granzymes trigger programmed cell death. This sequence links recognition to controlled target-cell elimination and helps researchers distinguish antigen-dependent killing from nonspecific cellular damage.
CTL activity can become biologically important beyond pathogen or tumor elimination when it is excessive or misdirected. In that setting, the same antigen-recognition and killing capacity studied for protection becomes relevant to tissue damage. Immunology research therefore examines not only whether CTLs remove abnormal cells, but also how their responses may produce harmful effects in tissues.
These cells help researchers analyze host protection when pathogens reside within cells, including viruses and bacterial pathogens that enter cells. The central questions concern whether infected cells present relevant antigen on MHC class I and whether recognition can lead to contact-dependent release of perforin and granzymes. CTL studies therefore connect pathogen biology with antigen-specific cellular defense.
Vaccine research uses CTL biology to examine whether an intervention can support antigen-specific cellular defense. Investigators focus on the connection between antigen presentation through MHC class I, T-cell receptor recognition, and subsequent target-cell elimination. This perspective complements broader immune assessment by asking whether vaccination may prepare responses relevant to infected or abnormal cells.
Cancer immunotherapy uses CTL biology as a framework for studying how antigen-specific immune recognition could be directed toward cancerous cells. Research attention centers on whether cancer-cell antigen presentation through MHC class I can engage T-cell receptors and connect recognition with perforin- and granzyme-associated programmed cell death. This makes CTL mechanisms relevant to therapeutic immune-design questions.